Biogen Idec, Inc. (BIIB) Misses Q1 EPS by 9c; Boosts FY14 Outlook
Get Alerts BIIB Hot Sheet
Price: $194.11 --0%
EPS Growth %: +0.9%
Financial Fact:
Income tax expense: 337M
Today's EPS Names:
SFST, VLTO, CLIR, More
EPS Growth %: +0.9%
Financial Fact:
Income tax expense: 337M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q1 EPS of $2.47, $0.09 worse than the analyst estimate of $2.56. Revenue for the quarter came in at $2.1 billion versus the consensus estimate of $2 billion.
First Quarter 2014 Performance Highlights
- AVONEX® revenues increased 2% compared to the first quarter of 2013 to $761 million. The total was primarily comprised of $476 million in U.S. sales and approximately $285 million in sales outside the U.S.
- TYSABRI revenues increased by 41% to $441 million as a result of recording 100% of TYSABRI revenues following our acquisition of complete rights to the asset in the second quarter of 2013. Global in-market sales for TYSABRI for the first quarter of 2014 decreased 3% compared to the first quarter of 2013.
- TECFIDERA revenues were $506 million. The total was comprised of $460 million in U.S. sales and approximately $46 million in sales outside the U.S.
- RITUXAN® and GAZYVATM net revenues from our unconsolidated joint business arrangement were $297 million.
Other Financial Results
- Revenues for FAMPYRA® and FUMADERMTM totaled $35 million in the first quarter of 2014, compared to $38 million in the first quarter of 2013.
- Royalty revenues totaled $38 million in the first quarter of 2014, compared to $33 million in the first quarter of 2013.
- Corporate partner revenues totaled $52 million in the first quarter of 2014 compared to $22 million in the first quarter of 2013.
- As of March 31, 2014, Biogen Idec had cash, cash equivalents and marketable securities totaling approximately $2.0 billion.
Biogen Idec, Inc. sees FY2014 EPS of $11.35-$11.45, versus the consensus of $11.32. Revenue growth is expected to be approximately 26% to 28%.
For earnings history and earnings-related data on Biogen Idec, Inc. (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan is worried about further S&P 500 sell-off potential
- Vertex (VERX) Reports Prelim Q1 Results
- Globe Life Inc. (GL) Misses Q1 EPS by 1c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, FDA, Guidance, Hot Corp. News, Hot Earnings, Hot GuidanceRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!